really don’t know which model they adopt to approach the market, “go to market model” is proven, digital market model could be new approach...Akili adopting a new in-house model superceeding the conventional pharmaceutical one which is way to expensive. What we have in the hand is an approved product & addressable market and let see how NHL management drive this going forward...will be surprised with news of 100mil rights sold in US or EU country or Akili offered NHL and unconditional bid of 0.15$ in 6 months from now!
NHL Charts, page-4482
-
- There are more pages in this discussion • 2,433 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TD1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.001(50.0%) |
Mkt cap ! $3.295M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $270 | 180K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 48256239 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 52992898 | 21 |
View Market Depth
| Last trade - 15.06pm 03/07/2024 (20 minute delay) ? |
| TD1 (ASX) Chart |